A Randomized Phase II Trial With Bevacizumab, Irinotecan and Cerebral Radiotherapy Versus Bevacizumab, Temozolomide and Cerebral Radiotherapy as First Line Treatment for Patients With Glioblastoma Multiforme.
Phase of Trial: Phase II
Latest Information Update: 08 Dec 2016
At a glance
- Drugs Bevacizumab (Primary) ; Irinotecan (Primary) ; Temozolomide (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- 29 Nov 2011 Actual end date (Nov 2011) added as reported by ClinicalTrials.gov.
- 29 Nov 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 28 Jun 2011 Planned end date changed from Feb 2011 to Dec 2011 as reported by ClinicalTrials.gov.